PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services. As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues. Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing. The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally. Why not get in touch to see how we can help you with your biosafety testing strategy?